Cassava | Big support - last chance to get in cheap?

“Cassava Sciences had a productive quarter with its research programs in Alzheimer’s disease,” said Remi Barbier, President & CEO . “As a result, we anticipate having top-line results for our Phase 2b study of PTI-125, our lead drug candidate for Alzheimer’s, earlier than mid-2020.”

Just keep in mind - the phase IIb data will be reported within days or a few weeks!

تعليق:

Stock of the year!